A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Last Updated   April 25, 2024 - 21:02
OVERVIEW
-
Gender
all -
Age
years -
Phase
phase 3The drug or treatment is given to large groups of people to confirm its effectiveness, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely. -
Sites
sites -
Status
Recruiting
SUMMARY
The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
CONDITIONS
- Erythrodermic Psoriasis
- Generalized Pustular Psoriasis
ELIGIBILITY
Inclusion Criteria:
* The study participant has a diagnosis of generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP) at screening. For GPP, a diagnosis must be classified based on the criteria for diagnosis of GPP by the Japanese Dermatological Association (JDA); for EP, has a history of plaque-type psoriasis. In addition, has an involved body surface area (BSA) of lesion greater than or equal to (>=) 80 percent (%) at baseline
* Candidate for phototherapy or systemic treatment for psoriasis (either naive or history of previous treatment)
* A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta-human chorionic gonadotropin [beta-hCG]) at screening and have a negative urine pregnancy test at Week 0 prior to administration of study intervention
* A male participant must agree not to plan to father a child while enrolled in this study or within 90 days after the last dose of study intervention
* A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after receiving the last dose of study intervention
Exclusion Criteria:
* The study participant has a total score of JDA severity index for GPP >=14 at baseline if participants have a diagnosis of GPP
* The study participant has a differential diagnosis of the erythroderma (for example, erythroderma caused by lymphoma or drug eruption) other than EP
* The study participant has a history of or current diagnosis or signs or symptoms of severe, progressive, or uncontrolled liver, renal; cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
* The study participant has a history of amyloidosis
* Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients
* The study participant who doesn't meet the criteria of prior/current concomitant therapy and/or history/conditions of infections
DETAILS
LOCATIONS
Country (1) | City or Province (12) | Status |
Japan | Hokkaido, 01 JR Sapporo Hospital |
RECRUITING
|
Japan | Ichinomiya Ichinomiya Municipal Hospital |
RECRUITING
|
Japan | Itabashi Ku, 13 Teikyo University Hospital |
RECRUITING
|
Japan | Kitakyushu-shi Hospital of the University of Occupational and Environmental Health |
RECRUITING
|
Japan | Kumamoto, 43 Kumamoto University Hospital |
RECRUITING
|
Japan | Nagoya Nagoya City University Hospital |
RECRUITING
|
Japan | Osaka, 27 Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital |
RECRUITING
|
Japan | Sendai, 04 Tohoku University Hospital |
RECRUITING
|
Japan | Shimotsuga Gun Dokkyo Medical University Hospital |
RECRUITING
|
Japan | Shinjuku, 13 Tokyo Medical University Hospital |
RECRUITING
|
Japan | Toyoake Fujita Health University Hospital |
RECRUITING
|
Japan | Tsu Mie University Hospital |
RECRUITING
|
Indicates 50+ sites in this region: click to zoom in.
Indicates 10+ sites in this region: click to zoom in.
Indicates < 10 sites in this region: click to zoom in.
Corresponds to individual site.